07 August 2025
: Case report 
Chemotherapy without Blood Products for Treatment of Acute Myelogenous Leukemia in an Anemic Jehovah’s Witness Patient
Unusual clinical course, Unusual setting of medical care, Clinical situation which can not be reproduced for ethical reasons
Rida Altaf ABCDE 1, Mousa Thalji EF 2, Sarah Crowder BDE 1, Kiera Brigh Turner BEF 1, Hatem Hassanein CE 2, Stephen Carlan CEF 3*DOI: 10.12659/AJCR.949145
Am J Case Rep 2025; 26:e949145
Table 3 Summary of 19 medications administered to the patient during the initial active management, including clinical findings.
| Medication or procedure performed | 1st admission | 2nd admission, Day 7 | Day 8 | Day 12 | Day 14 | Day 17 | Day 26 | Day 28 | Day 32 discharge home | 1 week after discharge and 2 and 3 months | 5 months after discharge | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bone Marrow Biopsy | 70% blasts (95% cellularity) consistent with AML | Residual leukemia with 10–15% blasts | ||||||||||
| Epoetin alfa | 20 000 U/day SC | 40 000 U once/week SC | Patient died at home | |||||||||
| Iron sucrose | 100 mg/day ×10 d IV | |||||||||||
| Folate | 1 mg/day PO | Resumed 1 mg/day | ||||||||||
| Vitamin B12 | 1000 mcg/day SL | Restarted 1000 mcg/day SL | ||||||||||
| Acyclovir | 400 mg, 2×/day PO | Restarted 400 mg 2×/day | ||||||||||
| Levofloxacin | 400 mg/day PO | Restarted 400 mg/day | ||||||||||
| Posaconazole | 300 mg/day PO | Restarted 300 mg/day | ||||||||||
| Leuprolide | 3.75 mg once per month ID | |||||||||||
| Tranexamic acid | 1000 mg 3×/day PO during menses | |||||||||||
| Azacytidine | 300 mg/day IV for 7 days | 75 mg/m ×7 d | ||||||||||
| Venetoclax | 100 mg/day PO for 7 days. Dose reduced due to posaconazole | |||||||||||
| Romiplostim | 5 mcg/kg per week SC | Discontinued | ||||||||||
| Cefepime | 2 g every 12 h IV | |||||||||||
| Vancomycin | 1 g every 12 h IV | Discontinued | ||||||||||
| Metronidazole | 500 mg every 8 h IV | Switched to 500 mg every 6 h PO | ||||||||||
| Levofloxacin | 400 mg/day PO | 400 mg/day PO | 400 mg/day PO | |||||||||
| Voriconazole | 100 mg every 8 h PO | 100 mg every 8 hours PO | ||||||||||
| Darbepoetin | 500 μg per week SC | 500 μg per week SC | ||||||||||
| Summary of 19 medications administered to the patient during the initial active management, including clinical findings. Chemotherapeutic agents are shown in yellow highlight. SL – sublingual; S.C. – subcutaneous; IV – intravenous; ID – intradermal; PO – oral. | ||||||||||||